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We conducted an overview of systematic reviews (SRs) summarizing the best evidence
regarding the effect of COVID-19 on maternal and child health following Cochrane methods
and PRISMA statement for reporting (PROSPERO-CRD42020208783).
Methods
We searched literature databases and COVID-19 research websites from January to Octo-
ber 2020. We selected relevant SRs reporting adequate search strategy, data synthesis,
risk of bias assessment, and/or individual description of included studies describing COVID-
19 and pregnancy outcomes. Pair of reviewers independently selected studies through
COVIDENCE web-software, performed the data extraction, and assessed its quality through
the AMSTAR-2 tool. Discrepancies were resolved by consensus. Each SR’s results were
synthesized and for the most recent, relevant, comprehensive, and with the highest quality,
by predefined criteria, we presented GRADE evidence tables.
Results
We included 66 SRs of observational studies out of 608 references retrieved and most
(61/66) had "critically low" overall quality. We found a relatively low degree of primary
study overlap across SRs. The most frequent COVID-19 clinical findings during pregnancy
were fever (28–100%), mild respiratory symptoms (20–79%), raised C-reactive protein
(28–96%), lymphopenia (34–80%), and pneumonia signs in diagnostic imaging (7–99%).
The most frequent maternal outcomes were C-section (23–96%) and preterm delivery
(14–64%). Most of their babies were asymptomatic (16–93%) or presented fever (0–50%),
low birth weight (5–43%) or preterm delivery (2–69%). The odds ratio (OR) of receiving inva-
sive ventilation for COVID-19 versus non-COVID-19 pregnant women was 1.88 (95% Confi-
dence Interval [CI] 1.36–2.60) and the OR that their babies were admitted to neonatal
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intensive care unit was 3.13 (95%CI 2.05–4.78). The risk of congenital transmission or via
breast milk was estimated to be low, but close contacts may carry risks.
Conclusion
This comprehensive overview supports that pregnant women with COVID-19 may be at
increased risk of adverse pregnancy and birth outcomes and low risk of congenital
transmission.
Introduction
Women undergoing pregnancy, and those at the time of childbirth and puerperium constitute
potentially vulnerable populations for COVID-19. Although our understanding of this disease
is growing every day, many answers are still needed about the diagnostics and the clinical man-
agement methods in these groups, the impact of the disease in pregnant women and newborns,
and the potential of mother-to-child transmission.
Although some living guidelines on COVID-19 target the pregnancy population, several
clinical questions regarding pregnancy and childbirth remain unanswered [1]. The rate of
COVID-19 in pregnant and recently pregnant women attending or admitted to hospital for
any reason was around 10%. Pregnancy, in general, does not significantly increase the risk of
being infected by SARS-CoV-2 [2].
The World Health Organization (WHO) stated that pregnant women or recently pregnant
women who are older, overweight, and have pre-existing medical conditions such as hyperten-
sion and diabetes seem to have an increased risk of developing severe COVID-19 [3]. In gen-
eral, there is a consensus that breastfeeding should be promoted due to its mutual benefits.
However, it is not well known whether the virus can be transmitted through breastmilk [4].
Systematic reviews (SRs) constitute an organized effort to collect and comprehensively syn-
thesize the best available evidence on a given topic. Through this panoramic review of SRs, we
aimed to answer a series of clinical questions about COVID-19 and pregnancy by summariz-
ing the body of evidence and highlighting the best reviews in completeness and methodologi-
cal quality.
Objectives
To summarize the clinical presentation, vertical transmission, and maternal and perinatal out-
comes in pregnant women with COVID-19 and their neonates.
Methods
We performed an overview of SRs or umbrella review (PROSPERO Registration number
CRD42020208783) following Cochrane methods [5] and the Preferred Reporting Items for
systematic Reviews and Meta-Analyses (PRISMA) statement [6] and a specific guideline for
overviews [7] (S1 File) for reporting.
Eligibility criteria
We included SRs that met the Database of Abstracts of Reviews of Effects (DARE) criteria [8]:
1) reported eligibility criteria, 2) adequate search, 3) data synthesis, 4) risk of bias assessment
and/or 5) individual description of included studies.
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To be included, SRs had to meet at least four of these criteria, the first three of which were
mandatory. The exposures of interest were defined as diagnosis of SARS-CoV-2 infection,
SARS-CoV-2 risk factors, diagnostic tests, or treatments. Pregnant women without interven-
tions or exposures under study, including active or inactive comparators, usual care, or pla-
cebo, were defined as comparison groups. Any pregnancy or neonatal outcomes, including
clinical presentation, laboratory, and radiological findings, were included (S2 File).
Search strategy
From January to October 2020 an experienced librarian searched the Cochrane Library, MED-
LINE, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), Science
Citation Index Expanded (SCI-EXPANDED), China Network Knowledge Information
(CNKI), WHO Database of publications on SARS-CoV-2, EPPI-Centre map of the current
evidence on COVID-19, guidelines published by national and international professional socie-
ties (e.g., ACOG, RCOG, FIGO), pre-print servers (ArXiv, BiorXiv, medRxiv, search.bioPre-
print), and COVID-19 research websites (PregCOV-19LSR, Maternal and Child Health,
Nutrition: John Hopkins Centre for Humanitarian health, the LOVE database) We also
searched the reference lists of included SRs. No language or publication status restrictions
were applied (The whole search strategy is presented in the S3 File).
Study selection data extraction and quality appraisal
Pairs of reviewers independently screened titles and abstracts. We retrieved all potentially rele-
vant full-text study reports/publications, and two reviewers independently evaluated the full-
texts, recording the reasons for exclusion of the ineligible studies. Disagreements were resolved
through discussion of the review team. This process was performed using the web-based soft-
ware COVIDENCE [9].
Pairs of reviewers independently performed the data extraction through an online extrac-
tion form previously piloted in five studies. We recorded publication date, number of included
studies, number of included participants, quality items, and the components of our research
questions (population, exposition, comparisons, and outcomes). Discrepancies were resolved
by consensus.
Pairs of reviewers independently assessed the quality of SRs through the AMSTAR-2 tool
[10]. The instrument has 16 items. It is not intended to generate an overall score but provides
a categorical rating based on critical domains: protocol register, adequacy of the literature
search, justification for excluding individual studies, risk of bias from individual studies being
included, appropriateness of meta-analytical methods, consideration of risk of bias when inter-
preting the results, assessment of publication bias. The overall quality or confidence in the
results of the review can be rated as “high” (no or one non-critical weakness), “moderate”
(more than one non-critical weakness), “low” (one critical flaw with or without non-critical
weaknesses), and “critically low” (more than one critical flaw with or without non-critical
weaknesses). Discrepancies were resolved by consensus. We did not assess the quality of the
included primary studies in the SRs nor the quality of reporting of each SR.
Synthesis of results
An analysis of the overlap of the primary studies included by each systematic review was per-
formed. Only primary articles with DOI numbers were included for this analysis. We pre-
sented all the outcome measures reported in the SRs with proportions, relative risks, odds
ratios, risk difference, and/or ’number needed to treat’ mean differences, standardized mean
differences, with 95% confidence intervals.
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The purpose of our study is to present and describe the current body of SRs evidence on
COVID-19 in maternal and neonatal health. Therefore, we synthesized the results of all rele-
vant SRs, regardless of topic overlap, considering that re-extracting and re-analyzing outcome
data from non-overlapping studies was unfeasible and outside the scope of this overview.
Additionally, for this scoping synthesis, we selected the best SR that answers a specific question
according to pre-defined prioritizing criteria: most relevant, most comprehensive, most recent,
and highest quality determined by AMSTAR-2 [10]. For these prioritized reviews, pairs of
reviewers independently assessed the risk of bias of the priori SR using the tool Risk of Bias in
Systematic Review (ROBIS) [11] and the GRADE approach evaluating the certainty of evi-
dence of each outcome [12, 13]. We did not assess the quality of the included primary studies
in the SRs nor the quality of reporting of each SR.
We presented summaries of the findings in a format suitable for decision-makers, previ-
ously validated during the SUPPORT project [14], focusing on low- and middle-income coun-
tries (LMICs) for selected research questions.
Pre-specified subgroups were designated by sampling frame (universal, symptom-based, or
risk-based testing), timing of suspicion/diagnosis (pregnancy or postnatal period), trimester of
suspicion/diagnosis (first, second or third), country income-level (high or low- and middle-
income country), and maternal risk status (low or high).
Results
The cumulative search retrieval was 608 records, 126 potentially eligible reviews were assessed
by full-text and 66 were included for clinical presentation in pregnant women (n = 39), mater-
nal outcomes (n = 44), clinical presentation in neonates (n = 28), neonatal outcomes (n = 41)
and vertical transmission (n = 46) (Fig 1).
Table 1 presents the included studies and S4 File the list of excluded studies with their
exclusion reasons. All the included SRs were conducted during 2020 all over the world.
Although all of them reported a qualitative summary, 18 also included a quantitative summary
[2, 15–31].
Among the primary studies included in these reviews, the main study designs were case
reports, case series, and other observational studies with or without a comparison group.
The number of included SARS-CoV-2 positive pregnant women was highly heterogeneous
across reviews. While the Li review [32] and the Mullins review [33] included only 19 of them,
the Allotey review [2] included more than ten thousand.
Fig 2 shows the percentual degree of overlap of included systematic reviews’ primary stud-
ies, which in general was low (In S5 File we listed all primary studies with DOI included by
each review and in S6 File the degree of overlap in absolute numbers).
Concerning the overall quality, based on AMSTAR-2 (see Table 1), most SRs were classified
as "critically low" (n = 61), four as "low" [2, 34–36], and only one as "moderate" [37]. For the
prioritized systematic reviews, we also used the ROBIS tool (one was classified as “low risk of
bias” [2], one as “unclear risk of bias” [38] and the other two as “high risk of bias” [37, 39]) (S7
File, by each domain). The mean ± standard deviation of non-negative classifications was
9.21 ± 2.51. The most common weaknesses (>50% of SRs with unmet domain) were: not
reporting the funding for the studies included in the review (n = 65), not providing a list of
excluded studies and justifying the exclusions (n = 61), not accounting for risk of bias (RoB) in
individual studies when interpreting or discussing the results of the review (n = 50), not pro-
viding a satisfactory discussion of any heterogeneity observed (n = 50), not providing a proto-
col (n = 47) and not using satisfactory techniques for assessing the RoB in individual studies
included in the review (n = 39).
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Below the main findings are described for the five available bodies of evidence identified in
our overview: clinical presentation in pregnant women, pregnancy outcomes, clinical presen-
tation in neonates, neonatal outcomes, and vertical transmission.
There was a high level of heterogeneity of the reported values for each outcome across the
included SRs. Table 2 shows these value ranges (The S8 File shows the total number of new-
borns and pregnant women included and the numerical data of each outcome at the review
level).
The main findings are described briefly below.
Clinical presentation in pregnant women
Thirty-nine reviews [2, 15, 16, 18, 19, 21–23, 25, 28–37, 39–58] showed information regarding
clinical manifestations during pregnancy. Fever and mild respiratory symptoms were the most
frequently reported symptoms and raised C-reactive protein level, lymphopenia, raised white
cell count and raised procalcitonin level were the most frequent laboratory findings. Signs of
pneumonia on X-rays or computed tomography (CT) were also frequently reported (Table 2,
Tables 1, 2 in S8 File).
The Allotey review [2] was chosen as the best review for reporting clinical presentation in
pregnant women diagnosed with COVID-19 according to predefined criteria described in the
methods section (Table 3 and S9 File). It reported that fever (40%), cough (39%, involving 28
studies and 8317 pregnant women), and dyspnea (19%) were the most common symptoms. It
also reported that raised C reactive protein levels (49%) and lymphopenia (35%) were the most
common laboratory findings. Regarding findings on X-rays or CT, ground glass appearance
had a prevalence of 69%, and any other abnormalities on CT had a prevalence of 65%. Finally,
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0253974.g001
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4 8/1/20 66 1787 1787 6 Critically
low
Only 2.8% of mother-infant pairs were tested
positive, and this finding is identical to percentages
reported in former coronaviridae outbreaks. In
contrast, 20% manifested with intrauterine hypoxia
alongside placental abnormalities suggestive of
heavy placental vasoocclusive involvement.
Abdollahpour
[59]
2, 3, 4 3/25/20 2 (29), 4
(4)
NA NA 10 Critically
low
The clinical features of these patients with COVID-
19 infection during pregnancy were parallel to
those of non-pregnant adults with COVID-19
infection. The main symptoms of pregnant women
with COVID-19 were fever and cough.
Leukocytosis (41%) and elevated neutrophil ratio
(83%) were unusually noted. Symptoms are mild to
moderate in pregnancy. No trustworthy evidence is
available yet to support the possibility of vertical
transmission of COVID-19 infection from the
mother–baby. Mother-to-child transmission of
respiratory viruses mostly happens via the birth
canal and during breastfeeding or close contact.
Akhtar [40] 2, 3 5/22/20 22 156 108 12 Critically
low
Most of the mothers received nasal oxygen therapy;
many received antiviral and antibiotic medications.
Maternal clinical manifestations reported were
fever (53%), cough (32%), fatigue/malaise (13%),
myalgia (11%), sore throat (5%), and shortness of
breath (8%). A marked lymphopenia was also
noted in many patients with COVID-19. The most
common maternal/fetal complications included
intrauterine/fetal distress (14%) and premature
rupture of membranes (PROM) (8%). The neonatal
clinical manifestations of COVID-19 commonly
included shortness of breath (6%), gastrointestinal
symptoms (4%), and fever (3%).





14 Low The spontaneous preterm birth rate was 6% (95%
CI 3% to 9%) in women with COVID-19. The odds
of any preterm birth (3.01, 1.16 to 7.85) were high
in pregnant women with COVID-19 compared
with those without the disease. A quarter of all
neonates born to mothers with COVID-19 were
admitted to the neonatal unit (25%) and were at
increased risk of admission (OR 3.13, 2.05 to 4.78)
than those born to mothers without COVID-19.
Increased maternal age (1.78, 1.25 to 2.55), high
body mass index (2.38, 1.67 to 3.39), chronic
hypertension (2.0, 1.14 to 3.48), and pre-existing
diabetes (2.51, 1.31 to 4.80) were associated with
severe COVID-19 in pregnancy.
Arabi [16] 2, 3 3/20/20 7 50 8 Critically
low
Seven studies involving 50 participants with
Positive test of COVID-19 were enrolled. Same
clinical characteristics in pregnant women as in
non-pregnant adults were observed, with cough
and fever as prominent symptoms. No vertical
transmission was seen.
(Continued)
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Ashraf [41] 2, 3, 4 4/14/20 21 90 2 (86), 4 (90) 9 Critically
low
The most common symptoms included fever,
cough, and dyspnea. The main laboratory findings
included leukocytosis, lymphopenia,
thrombocytopenia, and elevated C-reactive protein.
The most commonly reported complications were
preterm labor and fetal distress. Three mothers
were admitted to ICU and required mechanical
ventilation; among them, one died, and one was on
extracorporeal membrane oxygenation. 82/86
neonates were negative in RT-PCR, while four were
positive. Out of 92 neonates, one died, and one was
born dead.
Banaei [60] 2, 3, 4 4/10/20 13 123 35 11 Critically
low
The result of five neonates was positive for
SARS-CoV-2.
Bwire [73] 4 5/18/20 33 NA 205 12 Critically
low
The current evidence revealed a low possibility of
vertical transmission of COVID-19, and antibodies
against SARS-CoV-2 were detected among
vertically exposed but negative infants.
Caparros
Gonzalez [66]
3, 4 3/1/20 5 33 NA 6 Critically
low
All empirical studies in this review reported an
absence of vertical transmission of the coronavirus
from the pregnant mother to the developing fetus
Centeno-
Tablante [38]
4 5/15/20 37 77 77 14 Critically
low
19 of 77 children (25%) were confirmed COVID-19
cases based on RT-PCR assays, including 14
neonates and five older infants. Nine of the 68
analyzed breast milk samples from mothers with
COVID-19 were positive for SARS-CoV-2 RNA; of
the exposed infants, four were positive, and two
were negative for COVID-19.




43 mothers developed perinatal complications,
including preeclampsia, placenta previa, placenta
abruptio, fetal distress, premature rupture of
membranes, and uterine scarring.




No evidence of vertical transmission based on what
has been assessed so far
Della Gatta [43] 2, 3 3/16/20 6 51 11 Critically
low
Six studies that involved 51 pregnant women were
eligible for the systematic review. At the time of the
report, three pregnancies were ongoing; of the
remaining 48 pregnant women, 46 gave birth by
cesarean delivery, and 2 gave birth vaginally; in this
study, one stillbirth and one neonatal death were
reported.
Deniz [62] 2 4 6/1/20 50 606 606 7 Critically
low
Twenty neonates had evidence of SARS CoV-2
infection (positive RT-PCR results or elevated level
of SARS CoV-2 antibodies in serum samples)




A total of 1141 neonates were born of which, 281
(25%) were preterm (<37weeks). SARS-CoV-2
testing was positive for 39/1005 neonates (3.9%),
16/43 mother-baby dyads (37.2%) were preterm
(<37weeks), 9 (21%) were low birth weight (<2500
g), and 27 (62.8%) were born by cesarean section
(Table 2). All 43 were tested for SARS-CoV- 2
infections using nasopharyngeal or oropharyngeal
specimen, and 19 neonates (44.2%) have positive
RT-PCR for SARS-CoV-2.58 live-born SARS-CoV-
2 cases, 4 (7%) were congenital in origin (2
confirmed, one probable, and one not sure), 41
were acquired in the postpartum period, and the
remaining 13 neonates could not be classified due
to non-available
(Continued)
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Di Mascio [17] 2, 3, 4 3/13/20 2 (19), 3
(16), 4
(6)
2 (79), 3 (58) 2 (60), 4 (42) 10 Critically
low
An overt diagnosis of pneumonia was made in
9,1.8%nd the most common symptoms were fever
(82.6%), cough (57.1%), and dyspnea (27.0%). The
pooled proportion of cesarean delivery was 83.9%
(95%CI 73.8–91.9), perinatal death was 11.1% 84.8–
19.6), including three stillbirths and two neonatal
deaths. A total of 34.2% (20.3–49.5) of fetuses
suffered from fetal distress, and 57.2% (3.6–99.8) of
newborns were admitted to the NICU. None of the
newborns showed signs of vertical transmission
Diriba [18] 2, 3, 4 4/30/20 25 1271 1271 12 Critically
low
None of the studies reported transmission of
SARS-CoV2 from the mother to the fetus in utero
during the follow-up period
Duran [67] 2, 3, 4 4/17/20 20 NA 222 7 Critically
low
Out of the 222 newborns, 13 were reported as
positive for SARS-CoV-2. Five of the 20 studies
reported data on umbilical cord blood, placenta,
and/or amniotic fluid, all with no positive results.
Figueiro-Filho
[39]








We suggest that pregnant women are not more
affected by the respiratory complications of
COVID-19 when compared to the outcomes
described in the general population.
Furlan [44] 2, 3, 4 3/1/20 2 (27), 4
(22)
399 80 10 Critically
low
The most common symptoms reported by
pregnant women with COVID-19 were fever and
cough Positive SARS-CoV2 test in neonates: 4/80








There are nine maternal deaths reported. In
pregnant women, the most common symptoms
were fever (56%), cough (43%), myalgia (19%),
dyspnea (18%), and diarrhea (6%). Pregnancy
complications included delivery by cesarean
section (80%), preterm labor (26%), 44 fetal distress
(8%) and premature rupture of membranes (9%).
Amongst the neonates of COVID-19 mothers, 48
preterm birth (25%), respiratory distress syndrome
(8%), pneumonia (8%) were reported. There 49
were four neonatal deaths reported. Pneumonia
was diagnosed by CT scan imaging in 96% of
COVID-19 pregnant women. Vertical transmission
rate of SARS-CoV-2 is estimated to be 8%.
Gao [19] 2, 3 4/16/20 14 236 9 Critically
low
Positive CT findings (71%; 95%CI 0.49–0.93), fever
(51%; 0.35–0.67), lymphopenia (49%; 0.29–0.70),
cough (31%; 0.23–0.39), fetal distress (29%; 0.08–
0.49). Compared with non-pregnant patients,
pregnant women with COVID-19 had significantly
lower incidences of fever (pregnant women, 51%;
non-pregnant patients, 91%; P < 0.00001) and
cough (pregnant women, 31%; non-pregnant
patients, 67%; P < 0.0001). fetal distress (29%;
0.08–0.49), preterm labor (23%; 0.14–0.32), and
severe case or death (12%; 0.03–0.20).
Goh [20] 4 3/23/20 17 402 405 3 Critically
low
The average pooled incidence of vertical
transmission was 16 per 1000 newborns (95%CI
3.40 to 73.11)
Gordon [68] 4 5/12/20 8 NA 40 13 Critically
low
Of the ten reported cases, only three are likely to be
vertically transmitted, while seven occurred in the
post perinatal period and are likely to have been
postnatally acquired. All neonates had a mild
course, recovered, and were negative on re-testing.
(Continued)
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Pregnant patients with COVID-19 most commonly
presented with fever, cough, shortness of breath
and dyspnea, most of which possessed imaging
manifestations. The risk of premature delivery was
higher, leading to a high risk of NICU admission
and low neonatal birthweight. Vertical
transmission was found to be unlikely.
Hasan [74] 2, 3 3/31/20 29 NA NA 11 Critically
low
Evidence of higher perinatal complications puts
pregnant women in a further vulnerable condition.
Cautiousness is imperative during the clinical
management of pregnant women with COVID-19.
Hessami [75] 2, 3 7/20/20 10 37 12 7 Critically
low
37 maternal and 12 perinatal mortality cases. All
maternal deaths were seen in women with previous
comorbidities, of which the most common were
obesity, diabetes, asthma, and advanced maternal
age. Acute respiratory distress syndrome and
severity of pneumonia were considered as the
leading causes of all maternal mortalities. Fetal and
neonatal mortalities were suggested to be a result of
the severity of maternal infection or prematurity,
respectively. There was no evidence of vertical
transmission.
Huntley [34] 4 4/29/20 10 310 310 14 Low There were no cases of vertical transmission among
310 deliveries for which reverse-transcription
polymerase chain reaction data were made
available.
Juan [37] 4 4/20/20 18 174 174 14 Moderate Throat swab test in neonates: 4/174
Kasraeian [22] 2, 3 3/18/20 9 87 86 7 Critically
low
No evidence of vertical transmission has been
suggested at least in late pregnancy. No hazards
have been detected for fetuses or neonates.
Although pregnant women are at an
immunosuppressive state due to the physiological
changes during pregnancy, most patients suffered
from mild or moderate COVID-19 pneumonia
with no pregnancy loss.






The most reported clinical symptoms were fever
(63.3%), cough (71.4%), and dyspnea (34.4%). The
commonest laboratory abnormalities were raised
CRP or procalcitonin (54.0%), lymphopenia
(34.2%), and elevated transaminases (16.0%).
Analysis of conception products that may be
associated with vertical transmission was reported
in a minority of cases (placenta: 10.7%, amniotic
fluid: 5.5%, cord blood: 6.2%). Maternal bodily
fluid PCR positivity was rare (vaginal swab: 0%,
stool: 12.5%, breast milk: 6.7%).




Fever (66.7%), cough (39.4%), fatigue (15.2%), and
breathing difficulties (14.1%) were common. Of all
deliveries that occurred, 83.9% had gone through
the C-section, and around 30.4% of the total
deliveries were premature. Among these reviewed
cases, one maternal death and one neonatal death
were also reported following COVID-19 infection.
The birth weight of the babies was normal in most
cases, although 17.9% of the newborns had low
birth weight (LBW).
(Continued)
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Kotlyar [24] 4 5/28/20 38 NA 936 7 Critically
low
A pooled proportion of 3.2% (95% confidence
interval, 2.2–4.3) for vertical transmission. Severe
acute respiratory syndrome coronavirus two viral
RNA testing in neonatal cord blood was positive in
2.9% of samples (1/34), 7.7% of placenta samples
(2/26), 0% of amniotic fluid (0/51), 0% of urine
samples (0/17), and 9.7% of fecal or rectal swabs
(3/31). Neonatal serology was positive in 3 of 82
samples (3.7%) (based on the presence of
immunoglobulin M).
Li [32] 2,3 2/6/20 13 19 NA 7 Critically
low
The clinical symptoms such as fever and cough in
children with SARS infection are similar to that of
adult patients
Martins [4] 4 4/21/20 8 24 24 5 Critically
low
Most pregnant women had a cesarean delivery
(91.7%) and two neonates had low birthweight (< 2
500 g). placental tissues and breast milk showed
negative results for the presence SARS-CoV-2 by
RT-PCR test.




Most common symptoms were fever (62.9%) and
cough (36.8%). Laboratory findings included
elevated C-Reactive protein (57%) and
lymphocytopenia (50%). Ground-glass opacity was
the most common radiological finding (81.7%).
Most patients were delivered via a cesarean delivery
with a rate of 76.3% (95%CI 65.8–.84.2%). Thirty-
one of 94 neonates were delivered preterm (<37
weeks). In all cases, the amniotic fluid, placenta,
and umbilical cord samples all tested negative for
SARS-CoV-2, while 2 neonates had RT-PCR–
confirmed SARS-CoV-2 infection.
Melo [26] 2 3/1/20 38 279 NA 9 Critically
low
The main reported laboratory findings were
lymphopenia, elevated C-Reactive Protein (CRP),
Amino alanine transferase (ALT), and Aspartate
amino transferase (AST). In all symptomatic cases,
chest Computerized Tomography (CT) scans were
abnormal. Their signs and symptoms were all
similar to the non-pregnant population.
Mirbeyk [47] 4 NA 2 (17–
37), 4
(37)
364 219 8 Critically
low
17 studies examined samples of the placenta, breast
milk, umbilical cord, and amniotic fluid, and all
tested negative except one amniotic fluid sample.
Most mothers described mild to moderate
manifestations of COVID-19. Of 364 pregnant
women, 25 were asymptomatic at the time of
admission. The most common symptoms were
fever (62.4%) and cough (45.3%). Positive
SARS-CoV2 test in neonates: 11/219
Muhidin [48] 3 3/19/20 9 89 NA 11 Critically
low
The main reported laboratory findings were
lymphopenia, elevated C-Reactive Protein (CRP),
Amino alanine transferase (ALT), and Aspartate
aminotransferase (AST). In all symptomatic cases,
chest Computerized Tomography (CT) scans were
abnormal.
Mullins [33] 4 7/12/
1905
18 19 20 7 Critically
low
Delivering babies, 3 (16%) were asymptomatic, 1
(5%) was admitted to ICU and no maternal deaths
have been reported. Deliveries were 17 by
caesarean section, 2 by vaginal delivery, 8 (42%)
delivered preterm. There was one neonatal death.
(Continued)
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Mustafa [27] 4 4/2/20 6 NA 57 6 Critically
low
Vertical transmission and virus shedding in breast
milk are yet to be established.
Panahi [72] 4 3/30/20 14 NA 13 10 Critically
low
Vertical transmission of SARS-CoV-2 through
placenta and its short-term and long-term harm to
offspring is still unclear. Fetal distress, premature
labor, respiratory distress and even death. One case
with multiple organ damage and rapid disease
changes like adults. One case asymptomatic despite
high viral load
Pettirosso [49] 2, 3 5/23/20 54 3830 655 11 Critically
low
Asymptomatic infection occurred in 43.5–92% of
cases. Fever was the most common sign, occurring
in 10–100% of cases both at admission and
postpartum. 19 of a total 655 neonatal
nasopharyngeal swabs were SARS-CoV-2 positive
by rtPCR across ten studies. SARS-CoV-2 was not
identified in any of the 45 breastmilk samples
studies.
Rahman [50] 4 NR 8 NA NA 8 Critically
low
The first case of possible vertical transmission of
COVID-19 was reported in March 2020. Other
cases similarly showed neonates to be positive for
the COVID-19 virus, shortly after birth, while the
amniotic fluid, cord blood, breast milk after the
first lactation of their mothers were negative of the
virus. Not all neonates of COVID-19-positive
mothers acquired the disease. The potential of
vertical transmission of COVID19 should not be
ruled out
Raschetti [77] 4 8/30/20 74 NA 176 11 Critically
low
We report that 70% and 30% of infections are due
to environmental and vertical transmission,
respectively. Our analysis shows that 55% of
infected neonates developed COVID-19; the most
common symptoms were fever (44%),
gastrointestinal (36%), respiratory (52%) and
neurological manifestations (18%), and lung
imaging was abnormal in 64% of cases.
Rodrı́guez-
Blanco [64]




All three coronaviruses produce pneumonia with
very similar symptoms, being milder in the case of
SARSCoV2. Fever (75.5%) and pneumonia (73.5%)
were the most frequent symptoms in infected
pregnant women. The most frequent obstetric
complications were the threat of premature
delivery (23.5%) and caesarean section (74.5%). No
vertical transmission detected.
Rostami [78] 2 5/25/20 71 28 NA 7 Critically
low
D-dimer levels were found to be higher in non-
COVID-19 pneumonia patients than COVID-19
patients.
Segars [65] 3 4/6/20 79 162 162 8 Critically
low
Coronavirus Disease 2019 infection may affect
adversely some pregnant women and their
offspring.
Shi [28] 2 4/20/20 11 173 6 Critically
low
The incidence of elevated D-dimer was 82% (95%
CI: 75–89%), elevated neutrophil count was 81%
(69–91%), elevated C-reactive protein was 69%
(58–79%), and decreased lymphocyte count was
59% (41–75%)
Singh [76] 4 6/4/20 62 NA NA 9 Critically
low
There is evidence of significant placental pathology
in SARS-CoV-2 infection, but it is unclear what
effects there may be for early pregnancy.
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Smith [35] 3 NA 9 92 60 12 Low COVID-19-positive pregnant women present with
fewer symptoms than the general population and
may be RT-PCR negative despite having signs of
viral pneumonia. The incidence of preterm births,
low birth weight, C-section, NICU admission
appear higher than the general population.
Soheili [29] 2,3 4/1/20 11 177 NA 10 Critically
low
The most common signs and symptoms in
pregnant women are fever, myalgia, increased CRP,
increased LFT and Lymphopenia. All the pregnant
women admitted to the hospital had radiological
features of COVID-19 pneumonia in CT scan or
CXR. The pooled prevalence of neonatal mortality,
lower birth weight, stillbirth, premature birth, and
intrauterine fetal distress in women with COVID
19 were 4% (95%Cl 1–9%), 21% (11–31%), 2% (1–
6%), 28% (12–44%), and 15% (4–26%); respectively
Teles Abrao
Trad [51]




Placenta, amniotic fluid, umbilical cord blood,
breastmilk, gastric juice, urine, and feces were all
screened for SARS-CoV-2 in different studies and
were reported as negative, suggesting a possible
lack of vertical transmission. Additionally, one
patient who tested negative for SARS-CoV-2 PCR
had positive SARS CoV-2 IgM and IgG. Hence, the
possibility of vertical transmission is inconclusive
at this point.




The next most commonly observed symptom was
cough in 27 patients (40%). Symptom onset
typically occurred before delivery in 44 patients
(66%), after delivery in 21 patients (31%), and on
the day of delivery in 2 patients (3%). Preterm
birth, defined as gestational age less than 37weeks
old, was observed in 24 (20%) neonates. Amongst
81 (69%) neonates who were tested for
SARS-CoV2, 5 (6%) had a positive result. However,
amongst these 5 neonates, the earliest test was
performed at 16 h after birth, and only 1 neonate
was positive when they were later re-tested
Trevisanuto
[69]
1 5/1/20 26 NA 44 12 Critically
low
Most neonates with SARS-CoV-2 infection were
asymptomatic or presented mild symptoms,
generally were left in spontaneous breathing and
had a good prognosis after median 10 days of
hospitalization.
Trippella [36] 3, 2 4/18/20 37 275 4 (248), 4
(275)
14 Low The majority of pregnant women presented with
mild to moderate symptoms. SARS-CoV-2
infection in pregnant women appeared associated
with mild or moderate disease in most cases, with a
low morbidity and mortality rate. The outcomes of
neonates born from infected women were mainly
favorable. Out of the 191 tested neonates, 175
(92%) were negative.
(Continued)
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Trocado [53] 3 3/20/20 8 95 51 11 Critically
low
The most common symptoms presented were fever
(55%), cough (38%) and fatigue (11%). The most
frequent pregnancy-related complications were
premature rupture of membranes (PROM) (5%),
fetal distress (14%), and postpartum fever (8%).
Other related outcomes were gestational diabetes
(3%), vaginal bleeding (3%), gestational
hypertension (2%), placenta previa (2%),
preeclampsia (1%), oligohydramnios (1%),
polyhydramnios (1%) and low abdominal pain
(1%). The mean birth weight of these 40 neonates
was 2292g and 20% of the newborn infants had low
birth weight (<2500g). No Apgar scores <5 at 1
min or <7 at 5 min were reported.
Turan [54] 3 5/29/20 63 637 485 7 Critically
low
Most (76.5%) women experienced mild disease.
Uygun-Can
[30]
2 5/1/20 12 181 NA 8 Critically
low
Fever and cough are the most common symptoms
in pregnant cases with SARS-CoV-2 infection, and
91.8% (95% CI: 76.7–99.9%) of RT-PCR results are
positive. Abnormal CT incidence is 97.9% (95% CI:
94.2–99.9%) positive. No case was death.
Vakili [55] 2 NA NA NA NA 8 Critically
low
The most attracting and reliable markers in
pregnant women were leukocytosis and elevated
neutrophil ratio
Yang N [70] 4 3/26/20 18 114 84 11 Critically
low
Fever (87.5%) and cough (53.8%) were the most
commonly reported symptoms, followed by fatigue
(22.5%), diarrhea (8.8%), dyspnea (11.3%), sore
throat (7.5%), and myalgia (16.3%). There are
reports of neonatal infection, but no direct
evidence of intrauterine vertical transmission has
been found.
Yang Z [71] 4 4/20/20 22 NA 83 10 Critically
low
Three were confirmed with SARS-CoV-2 infection
at 16, 36, and 72 hours after birth, respectively, by
nasopharyngeal swab real-time polymerase chain
reaction (RT-PCR) tests; another six had elevated
virus-specific antibody levels in serum samples
collected after birth, but negative RT-PCR test
results. However, without positive RTPCR tests of
amniotic fluid, placenta, or cord blood.
Yang Z [56] 3 3/31/20 18 114 NA 9 Critically
low
Five case reports included sixteen breastfeeding
mothers with COVID-19. The first case report
showed that neonates of nine mothers with
COVID-19 were isolated immediately after delivery
and fed with formula. All samples of breast milk
from 6 mothers and throat swab from their infants
showed negative nucleic acid test results for
SARS-CoV-2. The second case report described a
familial cluster of SARS-CoV-2 infection.
Yee [31] 2, 3 7/20/20 11 9032 338 7 Critically
low
Pregnant women with COVID-19 have relatively
mild symptoms. However, abnormal proportions
of laboratory parameters were similar or compared
to general population. Fetal death and detection of
SARS-CoV-2 were observed in about 2%, whereas
neonatal death was found to be 0.4%.
(Continued)
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when compared to non-pregnant women of reproductive age with COVID-19, pregnant
women with the disease were less likely to manifest fever (OR 0.43, 95%CI 0.22–0.85) and
myalgia (OR 0.48, 95%CI 0.45–0.51).
Maternal outcomes
Forty-four reviews [2, 4, 15–19, 21–23, 25, 26, 29, 31–37, 39–41, 43–49, 51–54, 56–65] reported
at least one pregnancy outcome in pregnant women. The main findings are presented in
Table 3, Table 3 in S8 File. The most frequently reported outcomes were C-section and pre-
term delivery.
The Allotey review [2] was chosen as the best review for reporting maternal outcomes
according to predefined criteria (Table 3). It was reported that the prevalence of all-cause mor-
tality was 0.63%, severe COVID-19 was 13%, admission to an intensive care unit (ICU) was
4%, and required invasive ventilation was 3%.
When compared with non-pregnant women of reproductive age with COVID-19, the
reported odds of admission to the ICU was 1.62 (95%CI 1.33–1.96); and the reported odds of
required invasive ventilation was 1.88 (95%CI 1.36–2.60).
Risk factors associated with severe COVID-19 were age (OR 1.78, 95%CI 1.25–2.55), high
body mass index (OR 2.38, 95%CI 1.67–3.39), hypertension (OR 2.0, 95%CI 1.14–3.48), and

















Yoon [57] 4 4/15/20 28 223 221 11 Critically
low
Mothers with COVID-19 usually appeared with
fever (42.3%), cough (31.8%); myalgia (21.4%); and
dyspnea/short of breath (11.3%). 92.5% of
confirmed women had pneumonia on CT scan.
Leukocytosis was reported in 31.5% and
lymphocytopenia was in 43.3%. C-reactive protein
concentration (CRP) was elevated in 63.1%.
Neonate (25%) had fetal distress and delivered
prematurely with LBW (1580 g)22. All neonates
showed pneumonia on chest imaging. Regarding
pregnancy outcome, premature rupture of
membrane was reported in 12.7% and preterm
labor was reported in 22.7%. Fetal distress was
reported in There were two still-births 15,39.
Postpartum fever was reported in 34.3%. Reverse
Transcription-PCR tests of the breast milk,
placenta, amniotic fluids, and cord blood and
maternal vaginal secretions were negative for
SARS-CoV-2. Fetal death was reported in two
cases. 48 of 185 newborns (25.9%) were born
prematurely
Zaigham [58] 3 4/1/20 18 108 NA 8 Critically
low
Fever (68%) and coughing (34%).
Lymphocytopenia (59%) with elevated C-reactive
protein (70%)
Question (Q): 1. Prevalence, 2. Signs & Symptoms, laboratory or image of child or mother, 3. outcome (mortality, abortions, complications, etc.), 4. Vertical
transmission, 5 diagnostic accuracy, 6. Effectiveness (cost & effect) of Interventions
# Search date refers to the last search date if searches were performed at different times
�AMSTAR-2: number of non-negative items out of 16 items, AMSTAR-2 overall confidence: Critically low, Low, Moderate, High
https://doi.org/10.1371/journal.pone.0253974.t001
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Neonatal clinical presentation
Twenty-eight reviews [2, 15, 31, 33, 35–37, 39–42, 45, 47, 48, 51–54, 57, 60, 61, 63, 66–71]
reported information on the clinical presentation in neonates born from pregnant women
diagnosed with SARS-CoV-2 (Table 2, Table 4 in S8 File).
Respiratory distress syndrome, shortness of breath, and fetal distress were the most fre-
quently reported moderate to severe presentations.
Laboratory data (confirmed cases through Polymerase chain reaction [PCR], elevated
SARS-CoV-2 IgM, and IgG antibodies) and imaging data (radiographic pneumonia) were also
reported.
The Figueiro-Filho review [39] was chosen as the best review for reporting neonatal clinical
presentation according to predefined criteria (Table 3). This review involved almost 11,000
cases of COVID-19 and pregnancy in 15 different countries. The most frequent newborn com-
plications were admission to neonatal ICUs (NICUs) (18.5%), prematurity complications
(5.43%), respiratory distress syndrome (4.9%), and congenital abnormalities (3.3%). The rate
of neonatal hospitalization < 2 days was 62.4% and> 7 days 11.8%.
Neonatal outcomes
Forty-one studies [2, 16–19, 21–23, 25, 29, 31, 33–37, 39–41, 43–45, 47, 48, 51–54, 57, 58, 60–
67, 69, 70, 72] presented neonatal outcomes of pregnant women diagnosed with SARS-CoV-2
(Table 2, Table 5 in S8 File). The most frequently reported neonatal outcomes were low birth
weight and preterm delivery.
The Allotey review [2] was chosen as the best review for reporting neonatal outcomes
according to predefined criteria (Table 3). The reported neonatal mortality prevalence was
Fig 2. Primary study overlap matrix (percentage) across included systematic reviews�. �The figure displays the 66
included SRs in both axis and the percentage of its primary studies overlap between two SRs. Only primary articles
with doi were included for this figure.
https://doi.org/10.1371/journal.pone.0253974.g002
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Table 2. Ranges of outcomes reported in the included systematic reviews�.
Dimension Outcome # of
studies






Asymptomatic 15 [2, 15, 22, 23, 33, 35, 36, 39, 42, 43, 49, 51, 52, 54, 55] 19 to 6598 4.8% to 41%
Pneumonia 10 [2, 18, 22, 35–37, 41, 45, 47, 64] 70 to 2577 6% to 100%
Mild respiratory
symptoms
34 [2, 4, 15, 16, 18, 19, 21–23, 29–32, 34–37, 39–47, 51–54,
56–58, 64]
19 to 8560 20% to
78.94%
Fever 35 [2, 15, 16, 18, 19, 21–23, 25, 29–32, 34–37, 39–47, 49,
51–53, 56–58, 64]
19 to 8571 27.6% to
100%




30 [2, 15, 16, 18, 21, 23, 25, 29, 30, 34–37, 39–44, 46, 49,
51–54, 56–58, 64]
32 to 1941 3.3% to 75.2%
Fatigue/malaise 20 [16, 18, 23, 29, 31, 34–37, 39–43, 46, 49, 52, 53, 56, 58] 35 to 680 6.45% to
30.49%
Myalgia 25 [2, 15, 16, 18, 21, 23, 29, 31, 34, 36, 37, 39–46, 49, 52–
54, 56–58, 64]
19 to 8372 1% to 43.5%
Diarrhea 22 [2, 15, 16, 21, 23, 25, 29, 31, 36, 37, 39, 41–43, 46, 49,
52–54, 56, 58, 64]
35 to 8310 0% to 15.6%
Mechanical ventilation/
IUC
17 [2, 15, 21, 23, 32–35, 37, 39–41, 44, 45, 51, 54, 64] 19 to 10713 1.4% to 83.6%
Death 21 [2, 16, 18, 21–23, 25, 32, 34–37, 41, 42, 44, 45, 47, 52,
54, 58, 64]
19 to 11580 0% to 15.78%
Raised reactive C protein 17 [2, 18, 23, 25, 28, 29, 31, 36, 37, 39, 41, 42, 48, 55, 57,
58]
30 to 592 27.59% to
96%
Lymphocytopenia 24 [2, 18, 19, 21–23, 25, 28, 29, 31, 32, 34–37, 39, 41, 42,
48, 51, 54, 55, 57, 58]
28 to 780 33.6% to 80%
Leukocytosis/
Neutrophilia
9 [2, 18, 28, 41, 42, 51, 54, 55, 57] 24 to 251 8.8% to 81%
Elevated ALT or AST 13 [2, 18, 21, 23, 25, 36, 37, 39, 41, 42, 44, 54, 55] 25 to 491 8.2% to 38.6%
Signs of pneumonia X
Rays or CT
10 [2, 19, 21, 32, 37, 41, 44, 51, 54, 57] 19 to 1968 7.1% to 99%
Maternal outcomes Preterm delivery 33 [2, 16–19, 21–23, 25, 29, 31, 33–36, 39, 40, 43, 45, 47,
51–54, 57, 60–63, 65–67, 70]
19 to 13118 14.3 to 63.8%
Vaginal delivery 22 [18, 21, 22, 29, 33, 35–37, 39–41, 43, 48, 51–54, 58, 60,
62, 64, 70]
19 to 1119 1% to 38.6%
C-section 35 [2, 4, 16–19, 21–23, 25, 26, 29, 32–37, 39–41, 43, 46–48,
51–54, 58, 60, 62–64, 70]
12 to 1125 23% to 95.8%
Preeclampsia 14 [16–18, 21, 29, 36, 37, 41, 43, 45, 48, 51–53] 10 to 381 0% to 26%
Stillbirth 21 [2, 17, 21–23, 29, 34, 36, 37, 41, 43–46, 48, 49, 54, 57,
58, 60, 70]
13 to 663 0% to 8%
Gestational diabetes 7 [36, 37, 41, 45, 51–53] 44 to 369 0.7% to 29%
Hypertension 8 [36, 37, 41, 43, 51–53, 64] 44 to 275 2% to 11.4%
Premature rupture of
membranes
18 [17, 18, 21, 22, 31, 33, 36, 40, 41, 43, 45, 49, 51–53, 57,
62, 64]
31 to 714 1% to 41%
Miscarriage or abortion 8 [18, 21, 32, 37, 44, 49, 54, 65] 10 to 743 0.5% to 14.5%
Intrauterine growth
retardation
5 [18, 32, 61, 64, 65] 13 to 162 0% to 23%
Fetal distress 22 [2, 15–19, 22, 23, 25, 29, 31, 35, 40, 41, 45, 48, 51–54,
65, 70]
18 to 369 0.1% to 46.7%
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0.34%, and neonatal admission to NICUs was 25% (95%CI 14%-37%). The neonates born to
mothers diagnosed with COVID-19 presented an odds ratio of admission to critical care unit
equal to 3.13 (95%CI OR 2.05–4.78) compared with those born to mothers without the disease.
Finally, the rate of overall preterm birth reported among pregnant women diagnosed with
COVID-19 was 17% (95%CI 13%-21%). No significant findings were observed for other neo-
natal outcomes.
Vertical transmission
Forty-six reviews [4, 15, 17, 18, 20, 21, 23–27, 31, 33, 35–39, 41, 42, 44, 45, 47, 49–52, 54, 56–
64, 66–68, 70, 71, 73–76] reported mother-to-child SARS-CoV-2 transmission (Table 2,
Table 6 in S8 File). Most studies only reported the proportion of infants’ positive cases without
evaluating breast milk or congenital/perinatal transmission. In the reviews reporting breast
milk or congenital/perinatal transmission the sample analyzed was generally small for these
outcomes.
Table 2. (Continued)
Dimension Outcome # of
studies






Asymptomatic 6 [31, 33, 35, 41, 63, 69] 20 to 86 16% to 93.2%
Fever 11 [15, 31, 36, 37, 40, 48, 60, 63, 66, 67, 69] 10 to 222 0% to 50%
Gastrointestinal
symptoms
9 [31, 36, 40, 48, 52, 60, 63, 68, 69] 10 to 160 1% to 8.1%
Shortness of breath 10 [31, 37, 40, 48, 52, 60, 63, 66, 67, 69] 10 to 222 0% to 60%
Respiratory distress
syndrome
9 [31, 36, 39, 41, 45, 51, 54, 60, 67] 86 to 576 0.8% to 11.1%
Mild respiratory
symptoms
5 [36, 37, 60, 67, 69] 34 to 222 0.8% to 20%
Elevated SARSCov2 IgM 6 [31, 42, 45, 61, 69, 70] 8 to 493 0.6% to 17.6%
Elevated SARSCov2 IgG 5 [31, 42, 45, 61, 70] 8 to 493 0.6% to 35%
Radiology pneumonia 7 [31, 36, 37, 45, 60, 67, 69] 21 to 369 0% to 71%
Neonatal outcomes Mortality 40 [2, 16–19, 21–23, 25, 29, 31, 33–37, 39–41, 43–45, 47,
48, 51–54, 57, 58, 60, 61, 63–67, 69, 70, 72]
10 to 1728 0% to 9.2%
Low birth weight (rate) 11 [21, 23, 29, 35, 39, 48, 51, 53, 57, 65, 70] 21 to 598 5.3% to 42.9%
Small for Gestational age 9 [31, 41, 48, 52, 54, 57, 60, 61, 66] 10 to 479 1.25% to 20%
Preterm (<37 weeks) 33 [2, 16–19, 21–23, 25, 29, 31, 33–36, 39, 40, 43, 45, 47,
51–54, 57, 60–63, 65–67, 70]
10 to 1872 2% to 68.8%
Low Apgar (<7) 11 [17, 18, 21, 34–36, 54, 60, 64, 65, 67] 17 to 361 0% to 18.76%
Admission to NICU 18 [2, 17, 18, 21, 23, 25, 33–35, 37, 39, 43, 45, 47, 51, 54,
60, 69]
10 to 1348 1.6% to 76.9%
Vertical transmission Placenta 15 [21, 23–27, 37, 41, 42, 47, 49, 54, 57, 62, 76] 1 to 63 0 to 12.7%
Amniotic 15 [21, 23–27, 35, 37, 41, 47, 52, 54, 57, 62, 63] 3 to 81 0 to 11.1%
Cord blood 12 [21, 23, 25–27, 35, 37, 47, 49, 52, 54, 57] 4 to 81 0 to 14.3%
Breastfeeding or breast
milk
21 [4, 21, 23, 24, 26, 27, 36–38, 47, 49, 51, 52, 54, 56, 57,
59, 62, 64, 70, 71]
6 to 82 0% to 19.8%
Respiratory droplets 21 [4, 15, 21, 24, 26, 27, 35–38, 41, 45, 49, 51, 54, 56, 57,
63, 68, 70, 71]
4 to 889 0% to 70.7%
SARS-CoV-2 cases in
neonates
44 [4, 15, 17, 18, 21, 23–27, 31, 33, 35–39, 41, 42, 44, 45,
47, 49, 51, 52, 54, 56–64, 66–68, 70, 71, 73–75]
4 to 1116 0% to 27.3%
� The S8 File presents the systematic review level data by research question, that were aggregated in Table 2.
CT: computed tomography
https://doi.org/10.1371/journal.pone.0253974.t002
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The Centeno-Tablante review [38] was chosen as the most appropriate review to answer
this question according to predefined criteria (Table 3 and S10 File). This review included 37
papers with a total of 889 infants. Of the 72 infected mothers whose breast milk samples were
laboratory-confirmed to contain the COVID-19 antigen, 14 infants were found to be infected
with COVID-19. Eight of the twenty-three infants that were breastfed were infected, two of the
eighteen infants that received a breast milk substitute were infected, two of four infants that
received mixed feeding were infected, and two of the twenty-three infants that did not report
Table 3. Key messages of prioritized systematic reviews.





What is the clinical presentation of pregnant
women with COVID-19?S Allotey 2020 [2]
Compared with non-pregnant women of reproductive age with
COVID-19, pregnant women may be less likely to manifest
symptoms. Fever, cough, dyspnea and ageusia may be the most
frequent symptoms.
310 to 8328 (3 to 29
studies)
��◯◯ Low
Raised C-reactive protein level, lymphopenia, raised white cell
count and raised procalcitonin level may be the most frequent
laboratory findings.
251 to 780 (5 to 15
studies)
��◯◯ Low
Ground glass appearance may be the most frequent radiological
finding
387 to 1960 (10 to 20
studies)
��◯◯ Low
What are the outcomes of pregnant women
with COVID-19? Allotey 2020 [2]
Compared with pregnant women without COVID-19, pregnant
women with COVID-19 may have more admissions to intensive
care units
1121 (1 study) ��◯◯ Low
Compared with pregnant women without COVID-19, pregnant
women with COVID-19 may have more deaths of any cause,
preterm births, and cesarean sections. However, the evidence is
very uncertain.
339 to 2167 (1 to 3
studies)
�◯◯◯ Very low
What is the clinical presentation of infants
born from pregnant women with COVID-19?
Figueiro-Filho [39]
The most frequent newborn complications were respiratory
distress syndrome (4.86%), sepsis (0.4%), congenital abnormalities
(3.3%), prematurity (5.43%) and admission to neonatal intensive
care units-NICU (18.45%)
241 to 992 (1 to 5
studies)
�◯◯◯ Very low
The rate of neonatal hospitalization < 2 days was 62.4%, 3–7 days
26.5% and > 7 days 11.8%.
245 (1 study) �◯◯◯ Very low
What are the neonatal outcomes born from
pregnant women with COVID-19? Allotey 2020
[2]
Compared with neonates born from women without COVID-19,
the neonates born from women with COVID-19 may have more
admissions to intensive care units
1121 (1 study) �◯◯◯ Low
Compared with neonates born from women without COVID-19,
the neonates born from women with COVID-19 may have more
deaths, and fetal distress and no important differences in abnormal
Apgar score at 5 minutes. However, the evidence is very uncertain.
376 to 1121 (1 study) ��◯◯ Very low
Do mothers transmit SARS-CoV-2 infection to
their offspring through breastfeeding?S
Centeno-Tablante 2020 [38]
Transmission via breastfeeding through other related bodily fluids,
(i.e., droplet transmission or airborne transmission due to close
contact with the infant or young child) could pose a risk to the
infant. However, the evidence is very uncertain.
77 children (37 studies) �◯◯◯ Very low
SARS-CoV-2 transmission via breast milk is very uncertain and the
risk of transmission via this route is estimated to be, at most, low.
82 breast milk samples
(37 studies)
�◯◯◯ Very low
Is there congenital transmission of SARS-CoV-
2 between mothers and children? Juan 2020
[37]
Apparently, vertical mother-to-infant transmission is low.
However, there is not enough good quality data to draw unbiased
conclusions.
155 children (19 studies) �◯◯◯ Very low
Congenital (umbilical cord blood and amniotic fluid) transmission
of SARS-CoV-2 is highly uncertain and the risk of transmission by
this route is estimated to be low at best. However, the evidence is
very uncertain.




S The policy briefs for these systematic reviews are available in S9 and S10 Files.
# The number studies and participants vary across different specific outcomes.
https://doi.org/10.1371/journal.pone.0253974.t003
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on feeding practice were infected. Regarding congenital/perinatal transmission cases, the Juan
review [37] was deemed to be the most appropriate review (Table 3). This review included 24
studies, case series, and case reports, including a total of 155 neonates. Ninety neonates were
tested for COVID-19, of which three were positive. The review also evaluated the presence of
SARS-CoV-2 in amniotic fluid (1/32), umbilical cord blood (0/34), and placenta (1/3). While
there was no vertical mother-to-child transmission, additional good-quality studies are needed
to determine whether vertical transmission is possible.
The key messages from the prioritized systematic reviews (by the most current search date,
the more significant number of included studies, and greater adequacy to address the out-
comes) are presented in Table 3.
Discussion
This systematic review of SRs integrated the most consolidated evidence synthesis regarding
the effects of COVID-19 on maternal and neonatal health.
Most SRs (92.4%) were classified as "critically low" in overall confidence, using the
AMSTAR-2 tool, likely due to the urgent demand of information for this hot topic. For the pri-
oritized systematic reviews, we also used the ROBIS tool (one was classified as “low risk of
bias” [2], one as “unclear risk of bias” [38] and the other two as “high risk of bias” [37, 39]) and
the GRADE approach for each of their outcomes. The certainty of evidence was rated as “low”
to “very low” due to study design, risk of bias, inconsistency and/or imprecision.
The COVID-19 related symptoms manifest from one third to two thirds less often in
pregnant women than in non-pregnant women of reproductive age [2]. While testing for
SARS-CoV-2 in non-pregnant women is usually based on symptoms or contact history, testing
in pregnant women is generally done for reasons that might not be related to COVID-19.
Affected women were at higher risk of requiring admission to an ICU or invasive ventilation.
Pregnant women with COVID-19 are also at an increased risk of receiving cesarean sections,
delivering preterm and their babies being admitted to a NICU. Higher age, higher body mass
index, and pre-existing comorbidities might be associated with severe disease [2]. Stillbirth
and neonatal death rates are low in women with suspected or confirmed COVID-19. However,
this evidence is based on a few large comparative studies. The substantial heterogeneity identi-
fied could be related to using different sampling techniques, the different sampling techniques,
and the differential baseline risk of participants [2].
Most infected neonates were asymptomatic. The most frequent symptoms were fever (0–
50%) or mild respiratory symptoms [39]. Low birth weight and preterm birth were the most
frequently reported neonatal outcomes. The neonates born to mothers diagnosed with
COVID-19 presented an odds three times higher admission to a NICU compared with those
born to mothers without the disease [2]. The risk of congenital transmission [37] or transmis-
sion via breast milk [38] is estimated to be low to very low, but there is a higher risk of trans-
mission due to close contact by droplet or airborne transmission.
The high rate of asymptomatic presentation in pregnant women with COVID-19 [2] may
be explained by the screening strategy for COVID-19 and the low thresholds for testing during
pregnancy. Even detecting more pregnant women with mild disease, higher admissions to the
ICU, or invasive ventilation were observed when they are compared with non-pregnant
women of reproductive age with COVID-19 [79]. A Swedish study also suggested an more
admissions to an ICU and higher requirement of invasive ventilation in pregnant women than
non-pregnant women [80].
Similar to the general population, pre-existing comorbidities seemed to be risk factors for
severity of COVID-19 in pregnancy [81]. Adverse outcomes related to COVID-19 were not
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found to be higher in women at the third trimester nor in multiparous ones—but the existing
sample sizes are not large (less than 300 women). Chronic hypertension and pre-existing dia-
betes were associated with maternal death in pregnant women with COVID-19, and both are
recognized risk factors in the general population. The low numbers of studies does not allow
to stablish the cause of death for these women. A slight increase in rates of preterm birth in
pregnant women with COVID-19 was observed when compared to those without the disease.
These preterm births could be medically indicative, since rates of spontaneous preterm births
in affected women were similar to those before the pandemic. More than 60% of pregnant
women underwent cesarean section in the non-comparative studies. This is three times the
global rate of cesarean sections worldwide [82], and deserves future research.
Surely, the precision will improve as more data is published. The overall rates of stillbirths
and neonatal mortality are not observably higher than the background rates. The indicators
for admissions to the NICU, of about 25% of neonates from affected mothers were not
reported. Countries’ regulations on isolation of exposed infants to the virus may have influ-
enced these rates.
Sixty-seven percent of newborns delivered by mothers with COVID-19 antibodies had
SARS-CoV-2 IgG, but not IgM antibodies [83]. This finding against vertical transmission is
consistent with our own findings of low to very low risk of this mechanism of congenital
transmission.
To our knowledge, there is only one overview of SRs published that reports maternal and
perinatal outcomes related to COVID-19 and pregnancy [84], including 52 SRs. This overview
searched studies until September 2020 and did not include 14 SRs that were found in our over-
view, probably explaining the lower level of overlap observed in our study. The authors did not
assess the quality of reporting of each SR, but they assessed the risk of bias of each included SR
using the ROBIS tool [11]. The high risk of bias identified in this overview is consistent with
the “critically low” confidence presented in our study by applying the AMSTAR-2 tool [10].
Initial studies involved women from China, but later in 2020, reports came also from
regional or national data from European countries and Latin America. The study design has
also changed from small case series and case reports to extensive observational data, with
recent studies also being comparative. Variations in the criteria for doing testing (symptoms-
based, close contact) and sampling methodologies explain differences in the prevalence of
COVID-19. Moreover, the findings only apply to women attending the hospital for any reason.
The true prevalence of COVID-19 in pregnancy is likely to be lower when all pregnant women
are included.
Strengths and limitations
This overview has several strengths. First, we followed sound methodology to conduct the
present overview of systematic reviews. Second, we included systematic reviews without lan-
guage restrictions. Third, we adhered to rigorous quality appraisal for the conduction of sys-
tematic reviews (AMSTAR-2 tool), which was independently assessed by pairs of reviewers
and discrepancies solved by consensus. We summarized and critically appraised an important
amount of evidence that is relevant to health decision-making (See examples of policy briefs in
S9 and S10 Files) and highlighted evidence gaps that could guide future research. Finally, we
conducted a sensitive and comprehensive search strategy to reduce the risk of missing relevant
studies. We synthesized the results of all relevant SRs, highlighting their overlap through a
matrix of primary studies by SR, and we also selected the best SR that answered a specific ques-
tion according to pre-defined criteria of relevance, comprehensiveness, data update, and qual-
ity. We presented these SRs through a summary of the findings tables with the certainty of
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evidence according to the GRADE approach. Our review integrated the evidence generated by
different independent groups, which could improve the robustness of our findings.
Our study is not exempt from limitations. A main limitation is that the last search was run
in October 2020. This is due to the time needed to perform a thorough SR. The general confi-
dence of the included SRs was ”critically low”, and the certainty of evidence was “low” to “very
low”. Additionally, there is a scarcity of data comparing pregnant women with non-pregnant
women or comparing pregnant women with and without COVID-19 [2]. We did not evaluate
the risk of bias of the primary studies, nor did we undertake a pooled analysis by the outcome,
as was originally stated in our protocol. Nevertheless, there was great heterogeneity of meth-
ods, study designs, and estimations that would preclude a meta-analysis.
Implications for clinical practice and research
Although pregnant women with COVID-19 could be less symptomatic than the general popu-
lation, the overall pattern is similar. However, the admission rates to ICUs and invasive venti-
lation in pregnant women with COVID-19 could be higher than non-pregnant women.
Mothers with pre-existing comorbidities will need to be considered as a high-risk group for
COVID-19, along with those who are obese and of advanced maternal age.
Physicians need to weight the need for antenatal visits against unnecessary exposure and
use of virtual meetings whenever possible. Infected pregnant women with before-term gesta-
tions might need care in special facilities for these cases since the neonates born to mothers
diagnosed with COVID-19 are at three times the risk of admission to NICUs compared with
those born to mothers without the disease.
Further data are needed to assess robustly if pregnancy-related maternal and neonatal com-
plications are increased in women with COVID-19 than those without the disease. Similarly,
the association between other risk factors, such as ethnicity and pregnancy-specific risk factors
such as preeclampsia and gestational diabetes on both COVID-19 related and pregnancy-
related outcomes needs evaluation. Preeclampsia was reported to be associated with severe
COVID-19 in small studies, but requires a further assessment as the clinical presentation of
severe preeclampsia could mimic worsening COVID-19 [85]. Robust registers of pregnancy
data by trimester of exposure are essential to determine the effects of COVID-19 on early
maternal and neonatal outcomes.
Systematic reviews of RCTs are the highest quality evidence to inform guidelines, and poor-
quality systematic reviews will still directly impact on clinical care. Despite urgency for evi-
dence, systematic reviews still need to adhere to the highest standards of reporting and con-
duction, more so in the presence of pre-prints, reports, and media statements. Primary studies
will need to explicitly state if duplicate data have been included to avoid double counting par-
ticipants in evidence synthesis. Individual participant data meta-analysis and network meta-
analysis of the emerging cohorts are critical to evaluate clinical manifestations and outcomes
by underlying risk factors and also to determine the differential effects of interventions to
reduce the complication rates.
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26. Melo GC, Araújo K. COVID-19 infection in pregnant women, preterm delivery, birth weight, and vertical
transmission: a systematic review and meta-analysis. Cadernos de saude publica. 2020; 36(7):
e00087320. https://doi.org/10.1590/0102-311x00087320 PMID: 32696830.
27. Mustafa NM, L AS. Characterisation of COVID-19 Pandemic in Paediatric Age Group: A Systematic
Review and Meta-Analysis. Journal of clinical virology: the official publication of the Pan American Soci-
ety for Clinical Virology. 2020; 128:104395. https://doi.org/10.1016/j.jcv.2020.104395 PMID: 32417675.
28. Shi L, Wang Y, Yang H, Duan G. Laboratory Abnormalities in Pregnant Women with Novel Coronavirus
Disease 2019. American journal of perinatology. 2020; 37(10):1070–3. https://doi.org/10.1055/s-0040-
1712181 PMID: 32396949.
29. Soheili M, Moradi G, Baradaran HR, Soheili M, Moradi Y. Clinical Manifestation and Maternal Complica-
tions and Neonatal outcomes in Pregnant Women with COVID 19: An Update a Systematic Review and
Meta-analysis. Research Square; 2020.
30. Uygun-Can B, Acar-Bolat B. Clinical Properties and Diagnostic Methods of COVID-19 Infection in Preg-
nancies: Meta-Analysis. BioMed Research International. 2020:1–8. https://doi.org/10.1155/2020/
1708267 PMID: 33029489. Language: English. Entry Date: In Process. Revision Date: 20201001. Pub-
lication Type: Article. Journal Subset: Biomedical.
31. Yee J, Kim W, Han JM, Yoon HY, Lee N, Lee KE, et al. Clinical manifestations and perinatal outcomes
of pregnant women with COVID-19: a systematic review and meta-analysis. Sci Rep. 2020; 10
(1):18126. https://doi.org/10.1038/s41598-020-75096-4 PMID: 33093582.
32. Li W, Tang J, Zeng Y, Yue Y, He Y, Zhang M, et al. A systematic review of SARS-infected pregnant
females, newborns, children and adolescents. Chinese Journal Of Evidence-Based Medicine. 2020; 20
(04):426–36.
33. Mullins E, Evans D, Viner R, O’Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review
and expert consensus. Cold Spring Harbor Laboratory; 2020.
34. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of Maternal and Peri-
natal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstetrics and gynecology.
2020; 136(2):303–12. https://doi.org/10.1097/AOG.0000000000004010 PMID: 32516273
PLOS ONE COVID-19 and pregnancy: An umbrella review
PLOS ONE | https://doi.org/10.1371/journal.pone.0253974 June 29, 2021 24 / 27
35. Smith V, Seo D, Warty R, Payne O, Salih M, Chin KL, et al. Maternal and neonatal outcomes associated
with COVID-19 infection: A systematic review. PLoS ONE. 2020; 15(6). https://doi.org/10.1371/journal.
pone.0234187 PMID: 32497090
36. Trippella G, Ciarcia M, Ferrari M, Buzzatti C, Maccora I, Azzari C, et al. COVID-19 in Pregnant Women
and Neonates: A Systematic Review of the Literature with Quality Assessment of the Studies. Patho-
gens. 2020; 9(6):25. https://doi.org/10.3390/pathogens9060485 WOS:000551563600001. PMID:
32570959
37. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect of coronavirus disease 2019 (COVID-19)
on maternal, perinatal and neonatal outcome: systematic review. Ultrasound in obstetrics & gynecology:
the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2020; 56
(1):15–27. https://doi.org/10.1002/uog.22088 PMID: 32430957
38. Centeno-Tablante E, Medina-Rivera M, Finkelstein JL, Rayco-Solon P, Garcia-Casal MN, Rogers L,
et al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review.
Annals of the New York Academy of Sciences. 2020. https://doi.org/10.1111/nyas.14477 PMID:
32860259
39. Figueiro-Filho EA, Yudin M, Farine D. COVID-19 during pregnancy: an overview of maternal character-
istics, clinical symptoms, maternal and neonatal outcomes of 10,996 cases described in 15 countries. J
Perinat Med. 2020. https://doi.org/10.1515/jpm-2020-0364 PMID: 33001856.
40. Akhtar H, Patel C, Abuelgasim E, Harky A. COVID-19 (SARS-CoV-2) Infection in Pregnancy: A System-
atic Review. Gynecologic and Obstetric Investigation. 2020. https://doi.org/10.1159/000509290 PMID:
32728006
41. Ashraf MA, Keshavarz P, Hosseinpour P, Erfani A, Roshanshad A, Pourdast A, et al. Coronavirus dis-
ease 2019 (COVID-19): A systematic review of pregnancy and the possibility of vertical transmission.
Journal of Reproduction and Infertility. 2020; 21(3):157–68. PMID: 32685412
42. de Sousa AFL, de Carvalho HEF, de Oliveira LB, Schneider G, Camargo ELS, Watanabe E, et al.
Effects of COVID-19 Infection during Pregnancy and Neonatal Prognosis: What Is the Evidence? Int J
Environ Res Public Health. 2020; 17(11):17. https://doi.org/10.3390/ijerph17114176
WOS:000542629600429. PMID: 32545378
43. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: a system-
atic review of reported cases. American Journal of Obstetrics and Gynecology. 2020; 223(1):36–41.
https://doi.org/10.1016/j.ajog.2020.04.013 PMID: 32311350
44. Furlan MCR, Jurado SR, Uliana CH, Silva MEP, Nagata LA, Maia ACF. Gravidez e infecção por Coro-
navı́rus: desfechos maternos, fetais e neonatais - Revisão sistemática^iptA Systematic Review of Preg-
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